What are the mechanisms of action of the different contraceptive methods to reduce the risk of ovarian cancer?

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Luo G, Li M, et al. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis. BMC Cancer. 2019;19(1):984.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–747.
   PubMed Web of Science ®Google Scholar
• Kim J, Park EY, Kim O, et al. Cell origins of high-grade serous ovarian cancer. Cancers (Basel). 2018;10(11):433.
   Web of Science ®Google Scholar
• Fleming JS, Beaugié CR, Haviv I, et al. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol. 2006;247(1–2):4–21.
   PubMed Web of Science ®Google Scholar
• Macciò A, Madeddu C. Inflammation and ovarian cancer. Cytokine. 2012;58(2):133–147.
   PubMed Web of Science ®Google Scholar
• Trabert B, Tworoger SS, O'Brien KM, et al. The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the ovarian cancer cohort consortium (OC3). Cancer Res. 2020;80(5):1210–1218.
   PubMed Web of Science ®Google Scholar
• Fathalla MF. Incessant ovulation–a factor in ovarian neoplasia? Lancet. 1971;2(7716):163.
   PubMed Web of Science ®Google Scholar
• Fathalla MF. Incessant ovulation and ovarian cancer - a hypothesis re-visited. Facts Views Vis Obgyn. 2013;5(4):292–297.
   PubMedGoogle Scholar
• Choi JH, Wong AS, Huang HF, et al. Gonadotropins and ovarian cancer. Endocr Rev. 2007;28(4):440–461.
   PubMed Web of Science ®Google Scholar
• Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55(1):3–23.
   PubMed Web of Science ®Google Scholar
• Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91(17):1459–1467.
   PubMed Web of Science ®Google Scholar
• Kotsopoulos IC, Papanikolaou A, Lambropoulos AF, et al. Serous ovarian cancer signaling pathways. Int J Gynecol Cancer. 2014;24(3):410–417.
   PubMed Web of Science ®Google Scholar
• Trabert B, Ness RB, Lo-Ciganic WH, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014;106(2):djt431–djt431.
   PubMedGoogle Scholar
• Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016;34(24):2888–2898. 10.1200/JCO.2016.66.8178
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42(7):918–931.
   PubMed Web of Science ®Google Scholar
• Tone AA, Salvador S, Finlayson SJ, et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol. 2012;10(5):296–303.
   PubMedGoogle Scholar
• Bergsten TM, Burdette JE, Dean M. Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: mechanisms and therapeutic implications. Cancer Lett. 2020;476:152–160.
   PubMed Web of Science ®Google Scholar
• Cardenas C, Alvero AB, Yun BS, et al. Redefining the origin and evolution of ovarian cancer: a hormonal connection. Endocr Relat Cancer. 2016;23(9):R411–R422.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303–314.
   PubMed Web of Science ®Google Scholar
• Ness RB, Grisso JA, Vergona R, et al. Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology. 2001;12(3):307–312.
   PubMed Web of Science ®Google Scholar
• Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.
   PubMed Web of Science ®Google Scholar
• Lee KC, Ngo-Metzger Q, Wolff T, et al. Sexually transmitted infections: recommendations from the U.S. preventive services task force. Am Fam Physician. 2016;94(11):907–915.
   PubMed Web of Science ®Google Scholar
• Ness RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health. 2004;94(8):1327–1329.
   PubMed Web of Science ®Google Scholar
• Xie X, Yang M, Ding Y, et al. Microbial infection, inflammation and epithelial ovarian cancer. Oncol Lett. 2017;14(2):1911–1919.
   PubMed Web of Science ®Google Scholar
• Nene NR, Reisel D, Leimbach A, et al. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. Lancet Oncol. 2019;20(8):1171–1182.
   PubMed Web of Science ®Google Scholar
• Lareau SM, Beigi RH. Pelvic inflammatory disease and tubo-ovarian abscess. Infect Dis Clin North Am. 2008;22(4):693–708.
   PubMed Web of Science ®Google Scholar
• Lin HW, Wang PH, Lee CY, Huang JY, et al. The risk of gynecologic and urinary tract cancer with pelvic inflammatory disease: a population-based cohort study. J Cancer. 2019;10(1):28–34.
   PubMed Web of Science ®Google Scholar
• Kisielewski R, Tołwińska A, Mazurek A, et al. Inflammation and ovarian cancer-current views. Ginekol Pol. 2013;84(4):293–297.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zeng F, Yuan J, et al. Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis. Cancer Causes Control. 2017;28(5):415–428.
   PubMed Web of Science ®Google Scholar
• Xu J, Peng JJ, Yang W, et al. Microbiomes and ovarian cancer: a review. Am J Cancer Res. 2020;10(3):743–756. Published 2020 Mar 1.
   PubMed Web of Science ®Google Scholar
• Kathawala RJ, Kudelka A, Rigas B. The chemoprevention of ovarian cancer: the need and the options. Curr Pharmacol Rep. 2018;4(3):250–260.
   PubMedGoogle Scholar
• Shafrir AL, Schock H, Poole EM, et al. A prospective cohort study of oral contraceptive use and ovarian cancer among women in the United States born from 1947 to 1964. Cancer Causes Control. 2017;28(5):371–383.
   PubMed Web of Science ®Google Scholar
• Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006;95(3):385–389.
   PubMed Web of Science ®Google Scholar
• Schüler S, Ponnath M, Engel J, et al. Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet. 2013;287(6):1187–1204.
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;122(1):139–147.
   PubMed Web of Science ®Google Scholar
• Cook L, Pestak C, Leung A, et al. Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk. Br J Cancer. 2017;116(2):265–269.
   PubMed Web of Science ®Google Scholar
• Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018;4(4):516–521.
   PubMed Web of Science ®Google Scholar
• Jatoi A, Foster NR, Kalli KR, et al. Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival. BMC Cancer. 2015;15(1):711.
   PubMedGoogle Scholar
• Huber D, Seitz S, Kast K, et al. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet. 2020;301(4):875–884.
   PubMed Web of Science ®Google Scholar
• Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju091.
   PubMedGoogle Scholar
• Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46(12):2275–2284.
   PubMed Web of Science ®Google Scholar
• Cibula D, Zikan M, Dusek L, et al. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011;11(8):1197–1207.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713–1727.
   PubMed Web of Science ®Google Scholar
• Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–4198.
   PubMed Web of Science ®Google Scholar
• Wilailak S, Vipupinyo C, Suraseranivong V, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG. 2012;119(6):672–677.
   PubMed Web of Science ®Google Scholar
• Rodriguez GC, Barnes HJ, Anderson KE, et al. Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen. Cancer Prev Res (Phila). 2013;6(12):1283–1292.
   PubMed Web of Science ®Google Scholar
• Lumbiganon P. Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary. Contraception. 1994;49(3):203–209.
   PubMed Web of Science ®Google Scholar
• Murdoch WJ, Van Kirk EA. Steroid hormonal regulation of proliferative, p53 tumor suppressor, and apoptotic responses of sheep ovarian surface epithelial cells. Mol Cell Endocrinol. 2002;186(1):61–67.
   PubMed Web of Science ®Google Scholar
• Ivarsson K, Sundfeldt K, Brännström M, et al. Production of steroids by human ovarian surface epithelial cells in culture: possible role of progesterone as growth inhibitor. Gynecol Oncol. 2001;82(1):116–121.
   PubMed Web of Science ®Google Scholar
• Jeon YJ, Cho JH, Lee SY, et al. Esculetin induces apoptosis through EGFR/PI3K/Akt signaling pathway and nucleophosmin relocalization. J Cell Biochem. 2016;117(5):1210–1221.
   PubMed Web of Science ®Google Scholar
• Iversen L, Fielding S, Lidegaard Ø, et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. BMJ. 2018;362:26.
   Google Scholar
• Van der Wijden C, Manion C. Lactational amenorrhoea method for family planning. Cochrane Database Syst Rev. 2015;2015(10):CD001329.
   Google Scholar
• Babic A, Sasamoto N, Rosner BA, et al. Association between breastfeeding and ovarian cancer risk. JAMA Oncol. 2020;6(6):e200421.
   PubMed Web of Science ®Google Scholar
• Stuebe AM, Rich-Edwards JW. The reset hypothesis: lactation and maternal metabolism. Am J Perinatol. 2009;26(1):81–88.
   PubMed Web of Science ®Google Scholar
• Huang Z, Gao Y, Wen W, et al. Contraceptive methods and ovarian cancer risk among Chinese women: a report from the Shanghai Women's Health Study. Int J Cancer. 2015;137(3):607–614.
   PubMed Web of Science ®Google Scholar
• Jareid M, Thalabard JC, Aarflot M, et al. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018;149(1):127–132.
   PubMed Web of Science ®Google Scholar
• Wheeler LJ, Desanto K, Teal SB, et al. Intrauterine device use and ovarian cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2019;134(4):791–800.
   PubMed Web of Science ®Google Scholar
• Teng P, Hao M. A population-based study of age-related associations between vaginal pH and the development of cervical intraepithelial neoplasia. Cancer Med. 2020;9(5):1890–1902.
   PubMed Web of Science ®Google Scholar
• Grandi G, Farulla A, Sileo FG, et al. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018;19(7):677–686.
   PubMed Web of Science ®Google Scholar
• Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385–394.
   PubMed Web of Science ®Google Scholar
• Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization collaborative study of neoplasia and steroid contraceptives. Cancer Epidemiol Biomarkers Prev. 1996;5(11):933–935.
   PubMedGoogle Scholar
• Cibula D, Widschwendter M, Zikan M, Dusek L. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand. 2011;90(6):559–563.
   PubMed Web of Science ®Google Scholar
• Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' Health Studies. Fertil Steril. 2014;102(1):192–198.e3.
   PubMed Web of Science ®Google Scholar
• Patil E, Jensen JT. Update on permanent contraception options for women. Curr Opin Obstet Gynecol. 2015;27(6):465–470.
   PubMed Web of Science ®Google Scholar
• Nezhat FR, Apostol R, Nezhat C, et al. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 2015;213(3):262–267.
   PubMed Web of Science ®Google Scholar
• Yoon SH, Kim SN, Shim SH, et al. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis. Eur J Cancer. 2016;55:38–46.
   PubMed Web of Science ®Google Scholar
• Callahan RL, Kopf GS, Strauss JF, 3rd, Tworoger SS. Tubal contraception and ovarian cancer risk: a global view. Contraception. 2017;95(3):223–226.
   PubMed Web of Science ®Google Scholar
• Kwon JS. Ovarian cancer risk reduction through opportunistic salpingectomy. J Gynecol Oncol. 2015;26(2):83–86.
   PubMed Web of Science ®Google Scholar
• Frishman GN. Prophylactic salpingectomy: does it make the cut? J Minim Invasive Gynecol. 2013;20(4):404–405.
   PubMed Web of Science ®Google Scholar
• Eleje GU, Eke AC, Ezebialu IU, et al. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018;8(8):CD012464.
   PubMedGoogle Scholar
• Temkin SM, Bergstrom J, Samimi G, et al. Ovarian cancer prevention in high-risk women. Clin Obstet Gynecol. 2017;60(4):738–757.
   PubMed Web of Science ®Google Scholar
• Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian cancer prevention and screening. Obstet Gynecol. 2018;131(5):909–927.
   PubMed Web of Science ®Google Scholar
• Shih IM, Wang Y. Wang Tl. The origin of ovarian cancer species and precancerous landscape. Am J Pathol. 2020:S0002–9440(20)30449–1.
   PubMed Web of Science ®Google Scholar